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ABSTRACT 
 
This is a prospective cross sectional descriptive study 
performed at Khartoum Teaching Hospital clinics in the period 
from January 2004  to July 2004. 
Aims: To diagnose patients with Graves’ disease among thyrotoxic 
patients by detection of TSI in their sera, to assess the frequency of 
Graves’ disease, and to study the clinical patterns of Graves’ 
disease. 
Patients & methods: Forty-nine patients with thyrotoxicosis 
(confirmed by laboratory investigations) were studied. Data was 
collected using designed questionnaire. TSI in the sera was 
detected by RIA. Frequency of Graves’ disease was determined. 
Symptoms and signs of the patients with TSI were studied. 
Results: Out of Forty-nine patients, thirty-four patients were 
found to have detectable significant level of TSI. Frequency of 
Graves’ disease amongst the patients was 69.4% . Main symptoms 
were dislike to hot weather (70%) , palpitation (35%), tremor (24%) 
infertility (20%), irritability (35%), fatigability (10%). 
Main signs were onycholysis (73%), proptosis (64%), tachycardia 
(44%) diffuse Goiter (30%), palmer erythema and anemia (7%), 
thyroid acropachy and pretibial myxodema (0%)  
Conclusion: Graves’ disease is the commonest cause of 
hyperthyroidism in patients with thyrotoxicosis in K.T.H. 
Diagnosis of Graves’ disease is done by detection of TSI in the 
patient serum. Dislike to hot weather and palpitation are major 
symptoms of Graves’. Proptosis is a major sign of Graves’. 
Onycholysis is common in Graves’ disease. 
Recommendations: Accurate diagnosis of Graves’ disease by high 
clinical suspicion and TSI detection in the patient serum. More 
studies for evaluation of radioactive iodine therapy in Sudan in 
order to extend it’s use in management of Graves’ disease. 
 
 
 
 
 
 
 
 
 
 
 
 
ﺔﺣوﺮﻃﻷا ﺺﺨﻠﻣ 
 
 هﺬﻩ دراﺳﺔ وﺻﻔﻴﺔ ﻋﻦ ﻣﺮض ﻏﺮاف أﺟﺮﻳﺖ ﻓﻲ ﻣﺴﺘﺸﻔﻰ اﻟﺨﺮﻃﻮم ﻓﻲ 
 .م4002اﻟﻔﺘﺮة ﻣﺎ ﺑﻴﻦ ﻳﻨﺎﻳﺮ وﺣﺘﻰ ﻳﻮﻟﻴﻮ 
ﻣﻦ أهﺪاف اﻟﺪراﺳﺔ ﺗﺸﺨﻴﺺ وﻣﻌﺮﻓﺔ ﺗﻌﺪد ﻣﺮض ﻏﺮاف ﺿﻤﻦ ﻣﺮﺿﻰ 
 .اﻹﻧﺴﻤﺎم اﻟﺪرﻗﻲ ، آﺬﻟﻚ دراﺳﺔ أﻋﺮاﺿﻪ وﻋﻼﻣﺎﺗﻪ اﻟﺴﺮﻳﺮﻳﺔ
ﻜﺸﻒ ﻋﻦ وﺟﻮد اﻷﺟﺴﺎم ﻓﻲ هﺬﻩ اﻟﺪراﺳﺔ ﺗﻢ ﺗﺸﺨﻴﺺ اﻟﻤﺮض ﺑﻮاﺳﻄﺔ اﻟ
 وﻣﻦ AIRاﻟﻤﻀﺎدة ﻟﻠﻤﺮض ﻓﻲ دﻣﺎء اﻟﻤﺮﺿﻰ وذﻟﻚ ﻋﻦ ﻃﺮﻳﻖ اﻹﺷﻌﺎع اﻟﻤﻨﺎﻋﻲ 
ﻣﻦ ﻣﺮﺿﻰ اﻹﻧﺴﻤﺎم اﻟﺪرﻗﻲ ﻳﻌﺎﻧﻮن ﻣﻦ ﻣﺮض % 4.96ﺧﻼل اﻟﺪراﺳﺔ وﺟﺪ ان 
 .ﻏﺮاف
أهﻢ أﻋﺮاض اﻟﻤﺮض اﻟﺠﺤﻮظ اﻟﺪرﻗﻲ ، ارﺗﻔﺎع ﺿﺮﺑﺎت اﻟﻘﻠﺐ وﺗﺤﻠﻞ 
 .اﻷﻇﺎﻓﺮ
اض اﻟﻐﺪة اﻟﺪرﻗﻴﺔ ﺑﻐﺮب اﻟﺴﻮدان ، وﻗﺪ أﺷﺎرت اﻟﺪراﺳﺔ ﻷهﻤﻴﺔ دراﺳﺔ أﻣﺮ
وأوﺻﺖ ﺑﻤﺰﻳﺪ ﻣﻦ اﻟﺪراﺳﺎت ﻋﻦ اﻟﻌﻼج ﺑﺎﻟﻴﻮد اﻹﺷﻌﺎﻋﻲ ﻓﻲ اﻟﺴﻮدان ﻓﻲ ﺣﺎﻻت 
 . ﻣﺮﺿﻰ اﻹﻧﺴﻤﺎم اﻟﺪرﻗﻲ
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LITERATURE REVIEW 
Graves’ Disease 
Background: 
Graves’ disease, named after Robert J. Grave’s, MD, Circa 1830  is 
an autoimmune disease characterized by hyperthyroidism due to 
circulating autoantibodies(1).  
Thyroid stimulating imrnunoglobulin (TSI) bind to and activate the 
thyroid stimulating hormone receptor; causing the thyroid gland to grow 
& the thyroid follicles to increase synthesis of thyroid hormones. 
Graves’ disease, along with Hashimoto’s thyroiditis is classified as 
autoimmune thyroid disorders(1). 
Graves’ disease is the most common ca of hyperthyroidism(2) in 
some patients, Graves’ disease represent part of a more extensive 
autoimmune process called autoimmune polyglandular syndrome(2) which 
also associated with pernicious anaemia vitiligo , diabetes mellitus type I, 
autoimmune adrenal insufficiency & systemic lupus erythromatosus(1). 
About 7 % of patients with Grave’s disease have vitiligo and 5 % of 
patients with Myasthenia Gravis have thyrotoxicosis at the same time(7). 
The natural history is one of alternating relapse and remission(2). 
The patients are usually hyperthyroidism but may be; or become, hypo- 
or euthryroid. 
Diagnosis requires identification of suppressed TSH level and 
elevated levels of free thyroxine (FT4) and/or tri-iodothyronine (T3) 
measurement of TSI (thyroid stimulating immunolgiobulins) is of interest 
but not required for therapeutic evaluation(3). 
Pathophysiology:- 
Some controversy continues over use of the terms hyperthyroidism 
and thyrotoxicosis. Some authorities prefer to use the thyrotoxicosis as 
the clinical condition that includes hyperthyroidism (then defined the 
increased synthesis and secretion of thyroid hormone) as one cause. 
The exact aetiology of Graves disease remains unknown but are 
likely related to a defect in immune tolerance leading to the development 
of a specific autoantibodies directed against various thyroid antigens and 
against proteins with putatively similar antigen sites in other tissues, 
notably, the subcutaneous tissues and extra  - ocular muscles(3).  
Yersina enterocolitica as well as E.coli and other Gram negative 
organisms, contain TSH binding sites(2). This raises the possibility that 
the initiating event in the pathogenesis may be an infection with possible 
molecular mimicry, in a genetically susceptible individual, but the precise 
initiating mechanism remains unproven(2). 
In view of varied manifestation and their differing courses, it’s 
possible that no single factor is responsible for the entire syndrome With 
respect to hyperthyroidism, the central disorder is a disruption of 
homeostatic mechanisms that normally adjust hormone secretion to meet 
the needs of peripheral tissues(6). This disruption results from the presence 
in plasma of an abnormal thyroid stimulator first recognized when it was 
shown the serum of patients with Graves’ disease releases radioiodine 
from prelabeled ginea pig or mouse thyroid (6, 35-51). 
In view of its prolong duration of action relative to that of TSH in 
this bioassay system ,this material was designated the long-acting thyroid 
stimulator (LATS). 
It was the first thyroid stimulating substance other than TSH to be 
identified and was later shown to be an IgG immunoglobulin (11). 
LATS activity in the mouse assay is due to thyroid  — stimulating 
immunoglobulins (TSI) of the IgG class elaborated by lymphocytes of 
patients with Graves’ disease(6). 
In Graves’ disease B- and T- lymphocytes mediated autoimmunity 
are known to be directed at well-known thyroid antigens, thyroglobulins, 
thyroperoxidase, sodium — iodide symporter, and the TSH receptor(1). 
However the TSH receptor itself is the primary auto- antigen of Graves’ 
disease and is responsible for the manifestation of Hyperthyroidism (1). 
Thyroid stimulating antibodies produced as part of the autoimmune 
react and bind to TSH receptor mimic the action of TSH (8). 
The hyperthyroidism results from the production of IgG antibodies 
directed against the TSH-receptor on the thyroid follicular cell which 
stimulates thyroid hormone production and in the majority Goitre 
formation, these antibodies are termed thyroid stimulating 
immunoglobulins or TSR-receptor antibodies (TRAb). and can be 
detected in the serum of most patients with Graves’ disease(12). 
 Under certain circumstances antibodies to the surface of a cell may 
stimulate rather than destroy .This would seem to be the case in 
thyrotoxicosis (Gravess’ or Basedow’s disease).There has long been 
indirect evidence suggesting a link between autoimmune processes and 
this disease: thyroid antibodies are detectable in up to 85 %  of 
thyrotoxicosis patients and histologically the majority of the glands 
removed at operation show varying degrees of thyroiditis and local 
antibody formation in addition to the characteristic acinar cell 
hyperplasia; thyrotoxicosis is found with undue frequency in the families 
of Hashimoto patients; there is an association with gastric autoimmunity 
in that 30 % have gastric antibodies and up to 10  %pernicious 
anaemia.The direct link came with the discovery by Adams and Purves of 
thyroid stimulating activity in the serum of thyrotoxic patients. Using a 
new bioassay they found that the serum caused a stimulation of the 
thyroid gland of the recipient animal which was considerably prolonged 
relative to the time course of action of the physiological thyroid 
stimulating hormone (TSH) from the pituitary; it was ultimately shown 
that this was due to the presence of thyroid stimulating antibodies 
(TSAb). These antibodies can block the binding of TSH to thyroid 
membranes and seem to act in the same manner as TSH, probably by 
stimulating the identical receptors .Both operate through the adenyl 
cyclase system as indicated by the potentiating effect of theophylline, and 
both produce similar changes in the ultrastructural morphology in the 
thyroid cell, but it is one of Nature’s ‘passive transfer experiments’ which 
links TSAb most directly with the pathogenesis of Graves’ disease. When 
TSAb from a thyrotoxic mother crosses the placenta it is associated with 
the production of neonatal hyperthyroidism , which resolves after a few 
weeks as the maternal IgG is catabolized. 
There is a good correlation between the titre of TSAb and the 
severity of hyperthyroidism. Because TSAb act independently of the 
pituitary-thyroid axis, iodine uptake by the gland is unaffected by 
administration of thyroxine or tri-iodothyronine, whereas normally this 
would cause feedback inhibition and suppression of uptake; this forms the 
basis of an important diagnostic test for thyrotoxicosis (26). 
There is reason to believe that enlargement of the thyroid in this 
disorder is due to the action of antibodies, which react with a ‘growth’ 
receptor and directly stimulate cell division as distinct from metabolic 
hyperactivity. In contrast, from patients with primary myxoedema contain 
antibodies capable of blocking the mitogenic action of TSH, thereby 
preventing the regeneration of follicles which is a feature of the enlarged 
Hashimoto. goiter. We see now that there is considerable diversity in the 
autoinimune response to the thyroid leading to tissue destruction, 
metabolic stimulation, growth promotion or mitotic inhibition which in 
different combinations account for the variety of forms in which 
autoimmune thyroid disease presents (12). 
In Caucasian there is an association of Graves’ disease with HLA- 
B DR and DR and with the inability to secrete the water soluble 
glucoprotein from the ABO blood group antigen coded for an 
chromosome 6, 19  respectively(12). 
Family studies showed that 50 %  monozygotic twins are 
concordant for hyperthyroidism as opposed to 5 %  of dizygotic twins(12).  
A study performed in Sudan 1980 showed absence of HLA-B8 in 
60 % of patients with Graves’ disease and in the same study TSI level was 
found to have direct relation with the degree of hyperthyroidism(28).  
The same study showed that TSI level always correlates well with 
the absence of control of thyroid by TSH as indcated by TRH TSH test 
and T3 suppression test except in patients with autoimmune thyroiditis 
and some patients with ophthalmic Graves’ disease who were found to be 
under control of TSH despite high level of circulating TSI(28). 
 Smoking is weakly associated with Graves’ disease but strongly 
linked with the development of ophthalopathy(12). 
The pathogenesis of the ophthalmic component is more anigmatic. 
One proposed mechanism is the development of antibodies against 
specific antigen in the extraocular muscles. 
Methods of visualization of extraocular muscle changes in thyroid-
related eye disease were examined by Fell et al. They showed infiltration 
of the spaces between the entraocular muscle fibre with monocellular 
amorphous inflammatory cells and an extracellular matrix(12). 
Nothing is known about the pathogenesis of the dermopathy(6).  
Frequency: 
In the US: Graves’ disease is the most common cause of 
hyperthyroidism. A study done in Olmstead country, Minnesota estimated 
incidence to be approximately 30 cases per 100,000 person per year(1). 
 Internationally the frequency of Graves disease as a cause of 
thryotoscicois ranges from approximately 60-90 %  in different regions of 
the world(1). 
In Wickham study in the United Kingdom, the incidence is 
reported as 100-200 cases per 100,000  population per year. 
 
 
 
Morbidity & Mortality: 
If left untreated, Graves’ disease can cause severe thyrotoxicosis.   
A life threatening thyrotoxcosis crisis can occur. 
Long — standing severe thyrotoxicosis leads to severe weight loss 
with catabolism of bone and muscle. 
Cardiac complications and psycho-cognitive complications can 
cause significant morbidity. Graves disease also is associated with 
ophthalmopathy and acropachy which can be disabling and can lead to 
total loss of hand function(1). 
Thyroid storm is severe hyperthyroidism ,acute mortality was 
100%, now with aggressive therapy and early recognition of the 
syndrome; the mortality rate remains approximately 20% (1). 
Clinical features: 
Although Graves’ disease most frequently occurs in women in the 
middle decade (8:1) more than men, it also occurs in elderly and in 
children(9). 
 Because Graves’ disease is an autoimmune disorder that also 
affects other organ systems, taking a careful patient history is essential to 
establishing the diagnosis(11). 
Patients usually present with complaints typical of thyrotoxcosis 
which include Weight loss, sweats, heat intolerance, nervousness, 
agitation, tiredness muscle weakness, tremor palpitation, shortness of 
breath (21). 
Grave’s disease is the most common ( 70-80% ) cause of thyrotoxicosis, 
other rare causes include: 
- toxic thyroid adenoma 
- toxic multinodular goiter. 
- Subacute thyroditis 
- Factitious thyrotoxicosis (14-20). 
Thyrotoxicosis usually develops insidiously, and most patients 
have had the symptoms for at least 3-6 months before presentation(14-20). 
 Almost every system is affected and patients may initially present 
to various medical specialties for example, to a cardiologist with atrial 
fibrillation, or to a neurologist with myopathy (14-20). 
Patients with Graves’ disease have specific clinical manifestation 
resulting form underlying autoimmune process(10). 
The thyrotoxicosis and autoimmune related manifestation can show 
independent variants in intensity and time course, causing diagnostic 
difficulties(10). 
Frequent complaints in patients with Graves’ disease include rapid 
heart rate, palpitation, nervousness, tremor, less common complaint 
include sleep disturbance, weight loss, heat intolerance, hyperdefication, 
inability to work, proximal muscle weakness and easy fatigability with 
physical activities. 
 Graves’ disease as with other autoimmune disease, affects females 
more common than males and has a female to male ratio of 7- 8 : 1  
Typically, it is a disease of young women, but it may occur at any age. 
The typical age range 20-40 years, affected women are aged 3 0-60 years. 
Symptoms of ophthalmopathy include proptosis, lid retraction, 
lacrimation, gritty sensation in the eyes, photophobia, eye pain, diplopia 
or even visual loss. 
In the elderly subjects with thyrotoxicosis the clinical picture is often 
significantly different, problems such as weight loss and depression or 
agitation may predominate- so called apathetic thyrotoxicosis, a condition 
in which more typical symptoms and signs reflecting sympathetic 
activation such as tremor and hyperactivity are absent 
The common signs are goiter which is typically symmetrical, painless, 
diffusely enlarged gland and a bruit is often audible over the thyroidIn 
general, the signs and symptoms of Graves’ disease are as follows 
 • General, metabolic:- basal metabolic rate, heat intolerance, increased 
sweating, restlessness, anxiety, irritability, insomnia, weight loss despite 
increase or similar appetite, easy fatigability. 
 • Dermatologic : - Warm, moists, skin, fine hair, onycholysis, vitiligo, 
alopecia, pretibial myxaedema palmer erthymema. 
 • Skeletal : increased bone turn over , ostoporosis, acropachy, elevated 
serum calcium and alkaline phophatase. 
• Cardiovascular: tachycardia, decreased systemic vascular resistance, t 
cardiac output, increased pulse, atrial fibrillation, left ventricular 
hypertrophy, cardiomyopathy angina pectoris. 
• Respiratory, dyspnoea, respiratory muscle weakness. 
• Gastorintestinal: Decreased gastrointestinal transit time, hyperdefication 
with or without diarrhea, elevated transaminases, 
• Ophthalmic: - lid lag , lid retraction, proptosis , diplopia, visual loss in 
severe optic nerve involvement. 
Renal: - increased GFR, polyuria, poly dypsia 
Endocrine / reproductive: 
Irregular menstrual periods, decreased menstrual volume, 
gynacomastia, impotence increased sex hormone- binding globulin level, 
decreased free testostenone levels, worsening diabetes control, decreased 
parathyroid hormone level 
Haemolytic: - increased blood volume, normocytic anaemia low 
normal to slightly depressed total WBC count with relative 
lymphocytosis and monocytosis low normal to slightly depressed 
platelets count. 
Lipid metabolism: decreased total cholesterol, decreased 
triglycerides Common physical finding include widening of the palpebral 
fissure, tachycardia, hand tremors, fine and usually bilateral, proximal 
muscle weakness, warm velvety skin .Depression, anxiety or signs of 
pyschosis may be evident. 
Hypokalaemic periodic paralysis is noticed to occur in thyrotoxic 
patient from Asian origin. Attack may resolve interferon beta-S.b and 
interleukin - 4 when used therapeutically may cause Graves’ disease 
Trauma to the thyroid also has been reported to be associated with 
Graves’ disease This may include surgery of the thyroid gland 
percutaneous injection of ethanol, and infraction of a thyroid adenoma 
Physical findings that are unique to Graves’ disease include: 
Ophthalmpathy, acropachy and pretibial myxoedema phthalmpathy 
is a hall mark of Graves’ disease 20-30 % of patient with Graves’ disease 
will have clinical evidence of ophthalmospathy Signs of corneal or 
conjunctional irritation include conjunctional injection and chemosis .A 
complete ophthalmic examination, including retinal examination and slit 
lamp examination by ophthalmologists is indicated if the patient is 
symptomatic. 
Pretibial Myxoedema is infiltrative dermopathy, is characterized by 
non-pitting infiltration by proteinaceous ground substance, usually in the 
pretibial area. It rarely occurs in the absence of Graves’ disease 
ophtha1mopathy. 
The lesion is often pruritic and erythmatous in its early stages and 
subsequently become browny. like ophthalmopathy, infiltrative 
dermopathy may appear years before or after hyperthyroidism [ pretibial 
myxaedma the area is tender and itchy. The lesions may also occur in 
other parts of the body such as the face and are due to infiltration of the 
mucopolysactharide nd hyaloronic acid. It occurs in 5 % of patients with 
Graves’ disease. It usually occur after the onset of treatment ( 4-30 ) 
months Thyroid acropachy: refers to finger clubbing associated with 
periosteal new bone formation occurring in patients with Graves’ disease, 
almost all patients have thyroid associated Ophthalmpathy and thyroid 
associated dermopathy Sub-clinical thyrotoxicosis. 
This is essentially a biochemical diagnosis, the finding of an 
undetectable, as opposed to low but detectable, serum TSH concentration 
being of more pathophisological significance. The most common cause of 
suppression of TS/H in the general population is exogenous thyroid 
hormone therapy, typically T Population surveys have shown that 
approximately one quarter of those prescribed long- term T display 
reduction in TSH suggestive of mild over treatment (this is deliberate in 
relatively small number of patients with a history of thyroid cancer. Since 
T is prescribed to about 5 % of the over 60’s this medication is a common 
cause of sub-clinical hyperthyroidism. 
There is only limited evidence to suggest that sub-clinical 
hyperthyroidism is associated with significant symptom but there is a 
growing of body of evidence that low serum TSH is associated with 
adverse effects partially in heart and bone. 
These findings suggest that data showing effects of mild hyperthyroidism 
on indices of cardiac functions do indeed translate into significant adverse 
influences, especially in elderly subjects. 
Similar adverse effects of subclinical hyperthyroidism on bone may occur 
of studies examining effects of subclinical hyperthyroidism on bone 
mineral density have concluded that there are significant reduction in 
post-menopoausal women, although these studies are mostly confined to 
subject taking T 
Diagnosis of hyperthyroidism: 
The diagnosis should be confirmed by measurement of  :-  
• TSH: usually present in low concentration. 
 •Free thyroxine in the serum , high concentration 
TSH concentration may be normal or increased if the cause of 
thyrotoxcosis is either a pituitary adenoma secreting thyroid stimulating 
hormone or resistance to thyroid hormone. 
The diagnosis of Graves’ disease depends on clinical history and 
examination. 
The thyroid gland might be impalpable in about 30 % of cases of both 
Graves’ disease and toxic nodular hyperthyroidism. The presence of 
thyroid autoantibodies 80-90% , (to thyroid proxidase TPO and/or 
thyroglubulin) is suggestive, but not diagnostic Graves’ disease. TSH 
receptor antibodies, are more specific for diagnosis. Such antibodies are 
usually negative in cases of toxic hyperthyroidism, if antibodies are 
positive, in the presence of a nodular goiter, both condtions may co-
exists. 
Radioisotope scanning, using technetium 99 or iodine-125 typically 
shows a diffuse pattern of uptake in Graves disease. 
- Detection of TSI, (thyroid stimulating immunoglobulin) is diagnostic 
for Graves’ disease. Thyroid stimulating autoantibodies gives 100% 
detection rate in Graves’disease. 
- Complete blood count with differential should be obtained as a baseline 
and with the development of fever or symptoms of infection- Liver 
function tests should be obtained to monitor for liver toxicity caused by 
thionamides. 
Treatment: 
Medical care: 
Treatment of Grave’s disease involves alleviation of symptoms and 
correction of the thyrotoxic state 
It also aims to prevent the development of deterioration of extra thyroidal 
manifestation, particularly ophthalmopathy  
B —blockers reduces unpleasant symptoms of sympathetic 
over-activity, there may also be an effect on metabolism of thyroxine 
Propranolol (120-240 mg/day) is the most commonly used Beta-blocker, 
although any could be used  20  once erthyroid state has been reached, the 
beta —blocker is discontinued. 
 Antithyroid drugs: 
These include  
- Thionaniide : which block the synthesis of thyroid hormone. 
- Iodine; which destroys the cells making thyroid horomone, iodine, an 
excess of which reduces the production of thyroid hormone by an 
unknown mechanism. 
Mode of action of thionamide is by inhibiting organification of iodine and 
by inhibiting the coupling of iodotyrosine to form T4 & T3  
Maximum effect is delayed until existing hormone store are exhausted ( 
for week). 
Thionamides: 
T 1/2, 4 hrs are commonly used. The drugs accumulate in the thyroid 
gland and may act for 3 0-40 hrs. 
Propyithiourcil : differs from other members of the group in that it also 
inhibits peripheral conversion of T4 to T3 
These drugs are used as principal therapy and as adjuvant to radioiodine 
to control the disease until the radiation achieves its effect, and to prepare 
patients for surgery. 
Clinical improvment is noticeable in about a week. All three drugs give 
similar results. Side effects include: allergy, lymphadenopathy, 
leukopenia which may proceed to agranulocytosis ( < 1:10,000) or a 
plastic anaemia ( due to idiosyncrasy rather than allergy ) 
Blood disorders are most common in the first 2 months of treatment. 
 
Carbimazole: 
Is given in a dose of 15-40 mg daily, occasionally a larger dose may be 
required. This dose is continued until the patient becomes euthyroid, 
usually after 4-8 weeks and the dose is then gradually reduced to a 
maintenance dose of 5-15 mg. Therapy is usually given for 12 to 18 
months. Children may be given carbimazole in an initial dose of 250 
microgram /kg three times daily, adjusted according to response, 
treatment in children should be undertaken by a specialist. Rashes and 
pruritis are common but they can be treated with antihistamines without 
discontinuing therapy. Alternatively propyithiouracil may be substituted. 
All patients should be advised to report any sore throat immediately 
because of rare complication.  
 
Propyithiouracil :- 
Is given in a dose of 200 to 400mg daily in adults and this dose is 
maintained until the patient becomes euthyroid; the dose may then be 
gradually reduced to maintenance dose of 50 to 150mg mg daily. 
Antithyroid drugs only need to be given once daily because of their 
prolonged effect on the thyroid. Over-treatment can result in the rapid 
development of hypothyroidism and should be avoided particularly 
during pregnancy, because it can cause fetal goiter h134 A combination 
of carbimazole, 40 to 60 mg daily with levothyroxine , 50 to 150 
micrograms daily, may be used in a blocking —replacment regimen; 
therapy is usually given for 18 months. The blocking-replacment regimen 
is not suitable during 
 Pregnancy: 
The drugs cross the plancenta . Propyithiouracil is more safe during 
pregnancy and lactation. 
A major disadvantage of antithyroid drugs is relapse in (50- 70%) of 
cases in a few months or years. 
 
Radioiodine: - 
Is increasingly used as treatment of choice in hyperthyroidism at all ages. 
It is simple and in no way unpleasant and it carries no immediate 
mortality, but it is slow and appropriate dose may be difficult to judge It 
is indicated in Graves’ disease with moderate goiter (40-50 g), with no 
significant eye signs at first presentation. Exacerbant of symptom may 
occur in the first 2 weeks. It is contraindicated in pregnancy and lactation 
and with allergy to iodine. Radioactive iodine may cause transit 
hypothyroidism or hyperthyroidin ( Jod Basedow phenomenon)  
 
 
 
Surgery: 
Indication for thyrodectomy include: 
- Allergic reaction to medical treatment: 
- Disease refractory to high dose medical treatment. 
- Relapsing disease 
- Contraindication to treatment with iodine( 14-20). 
 
Management of Graves’ ophathalmopathy: 
Aims: 
- relieve symptoms 
- suppress the disease process 
- restore muscle mobility 
- improve cosmotic appearance 
Management include: 
- Simple Elevation of the head of the bed 
• Diuretics 
• Dark glasses 
- Local: 
• Artifical tears 
• Orbital radiotherapy 
• Tape eyes shut at night 
- Surgical: 
• Tarsorrhophy 
• Orbital decompression 
- Immunomodulation 
- Prednisolone and methypredinosolne 
- Plasma exchange 
- Cyclosporine and azathioprine 
 
 
Management of Pretibial myxadema: 
For milder cases no treatment is required (1). 
Topical steroid applied under occlusive plastic film for 3-10 weeks 
have been helpful(1). 
In severe cases pulse glucocoriticoid therapy may be tried. 
For Acropachy: 
No therapy has been proven to be effective (1). 
  
OBJECTIVES 
 
The main objectives of this study are: 
- To diagnose patients with Graves’ disease by detection of TSI in 
their sera. 
- To assess exactly the frequency of Graves’ disease among 
thyrotoxic patients. 
- To stand upon the main clinical features in patients with Graves’ 
disease. 
 
MATERIALS AND METHODS 
 
This study is an outpatient based prospective one, in which 49 patients 
were studied. It is carried out in Khartoum Teaching Hospital and its 
referral clinics in the period of January 2004 — July 2004. Formal 
acceptance from all patients to be included in the study was taken 
beforehand with simple explanation about the study. 
All of the patients were already diagnosed as thyrotoxic confirmed by 
laboratory investigations, namely, their thyroid function tests. The 
patients ho are already on treatment were also included. 
The history of their disease was taken comprising personal data and 
symptomatology. Then clinical examination of the patients was 
performed. 
The last laboratory investigations regarding their thyroid functions were 
recorded and their blood was then taken for analysis to detect (TSI) in the 
sera. Results were tabulated. Data obtained was then statistically analyzed 
using soft SPSS programme. 
Lab investigation: 
TSI can be detected either by RIA ‘ or by ELISA” Enzyme- linked 
immunosorbant assay. 
The RIA offers high sensitivity specificity, accuracy and precision.’ Basic 
principle of RIA depends on detection of low concentration of antigenic 
hormone by determinating the ability of these antigens to be bound by 
specific antibodies. The assay is established by: 
1. Obtaining the component necessary to perform the assay. 
2. Allowing the component to interact under proper circumstances. 
3. Separating specific component. 
4. Measuring those component by radioactive tracer measurement 
technique. 
5. Obtaining measurement of series of known quantities of substance for 
later comparison to an unknown amount in the patients sample.  
All the above mentioned steps were done. Calculation were done using 
Gamma counter technique. 
Tabulated results were then analyzed staftstically using SPSS 
Programme. 
 
RESULTS 
 
• Out of the 49 patients studied, thirty four patients were found to have 
the TSI, which means a frequency of 69.4%. 
 
• As to gender distribution, the females dominate “Figure 1”, the 
percentage being 85% females compared with 15% males. 
 
• The results showed that the peak age group affected is age group 35-44 
years “Figure 2”. 
 
• Figure 3 shows the residence distribution, Khartoum town being 41.2%, 
followed by Omdurman town 35.3% . Other states 8.8%. 
 
• Distribution of patients by tribes “Figure 4”, showed that most of the 
patients are of the western Sudanese tribes 52.9% followed by Northern 
tribes 29.4%, the smallest percentages were those from Eastern and 
Southern tribes. 
 
• Socioeconomic state of the patients was also studied “Figure 5”, which 
showed 52.9% were of low state compared with only 2.9% of high 
socioeconomic state. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
• Figure 6 studied the marital state in patients with Grave’s disease and 
showed that 56% are married, 41% are single and 3% found to be 
divorced. 
 
• Main Symptoms of the patients were shown in Figures:”7,8&9” it 
showed dislike to hot weather is a major complaints in 70%, followed by 
irritability and palpitation each accounting for 35% , goitre in 30% 
sweating in 25%,tremor 24%. Weight loss 23%, infertility 20%, 
oligomenorrhoea 15%, frequent stool 13% and fatiguability 10%. 
 
• Clinical examination of the patients is shown in Figures 10,11 &12, it 
revealed onycholysis is the main sign in patients under study accounting 
for 73% followed by proptosis 64%,” including one patient with 
unilateral proptosis”, diffuse goitre 53.4%, tachycardia 44.8%, bruit over 
the gland 29%, lid lag 13%, ophthalmoplegia, plamer enythem and 
anaemia each 7% and atrial fibrillation 1.7%. Non of the patients showes 
pretibial myxoedema, thyroid acropachy or optic nerve compression. 
 
• TSH level being the most important hormone to be studied regarding 
thyroid functions was found to be low in 62%. Normal in 26% not done 
in 12% .“Figurel3” 
 
 
• T3 level was found to be high in 82% of patients. “Figure 14”. 
 
• T4 level was found to be high in 79% of patients. “Figure 15”. 
 
• Figure 16 discussed the mode of treatment taken by the patients under 
study and it shows 58.8% of patients taking antithyroid, 50% taking Beta 
blockers, only 2.9% underwent radioactive iodine therapy, none of the 
patients undergone surgery. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DISCUSSION 
 
? The frequency of Graves’ disease obtained by detection of TSI, is 
found to be 69.4%, showing Graves’ disease to be the commonest 
cause of hyperthyroidism in the thyrotoxic patients of K.T.H, this 
is actually comparable with the international frequency of Graves’ 
disease 60-90%, according to Wick ham’s study in the United 
Kingdom the incidence was reported as 100-200 cases per 100,000 
population per year. Another study in U.S in Minnesota estimated 
incidence to be approximately 30 cases per 100,000 person per 
year. Our study also agrees with Yagi’s [ et al, who reported 
Graves disease in 18.52% out of 23.77% thyrotoxic. Their study 
depended on the clinical findings to diagnose Graves’ disease. 
? Most of the patients in this study were residing in Khartoum 
(41.2%), Omdurman 35.3%. This actually agrees with Kambal’s 
study, 1967 in which he showed Khartoum area to be endemic for 
Goitre. Another observation is that the big hospitals are found in 
these areas within an easy reach of the patients, this would possibly 
explain their crowding in these areas. 
? Most of the patients with Graves’ disease in this study were from 
western tribes, this is also found to be in line with Kambal’s(29) et al 
(1952) who showed Darfur Province in the western region to be 
endemic for Goitre. Woodman’s(30) et al (1952) also described 
Darfur area as endemic for Goitre. 
? The females to males ratio was 5-6:1 which showed female 
domination but the ratio is less than that mentioned in the literature 
(7-8:1). Yasir’s(31) et al found the ratio to be 6.5.%. This reduced 
ratio in our study could be attributed to the small number of the 
study population. 
? The mean age group affected in our study was found to be 35- 44 
years, which is in line with the literature where the range is 20-40 
years. 
? The study showed the main symptoms of the patients studied were 
irritability (3 5%), palpitation 35%, tremor 24%, Yasir’s study(31), 
showed tremors in 76.2% of patients. This smaller figure in our 
study could be explained by the fact that Yasir’s et al included 
patient who didn’t start treatment whereas in our study we have 
included patients who are already on treatment. These symptoms 
are mentioned in the literature to be frequent symptoms. 
? Other major complaint in our patient was dislike to hot weather 
(70%), which is mentioned in the literature to be a less common 
complaint(10). This could be explained by the fact that our country’s 
climate is hot most months of the year, which adds to their 
symptomatology. 
? Other symptoms in our study were found to be infertility (20%) , 
fatigability (10%) and frequent stool (13%) not common in our 
patients which is also similar to the literature. 
? The main clinical signs found in our patient were onycholysis 
(73%). This is actually different from the literature in which it is 
mentioned to be a less common feature of Graves’ disease(1).  
? Proptosis in our study was found in 64% of patients with Graves 
disease, this is comparable with Randeva(32). et al, who prescribed 
the condition 60% of cases. 
? Tachycardia is a major sign in our study group (44%) which is 
similar to the literature Atria1 found only in 1 7% of our study 
group (44%) which is similar at the literature. Atrial fibrillation 
was dound only in 1.7% of our patients. 
? Diffuse Goitre was found in 30% of patients in our study which is 
different from Randeva(32) et al who prescribed the condition in 
90% of patients. 
? Palmer erythema as a clinical finding in Graves’ disease was 
evident in 7% of our patients, Anaemia was found in 7% of 
patients. 
? None of our patients showed optic nerve compression. This also 
agrees with the literature in which signs are mentioned to be rare. 
? Thyroid acropachy was not detected in any of our patients, this is 
actually near to Randeva et al(32), who prescribed the condition in 
less than 1% of patients. 
? Albrights’ et al(33) did not mention acropachy as a sign in the guide 
lines for the diagnosis of thyroid disorders. 
? None of the patients in this study was found to have pretibial myxo 
edema, Yasirs’(31) showed the condition in about .2.4% of patients, 
which mean that it is a rare clinical finding. 
? TSH was found to be low in 62% of patients, normal in 26% of 
patients and not done in 12% of patients . Theses unexpected 
findings of normal TSH could be explained by the fact that some of 
the patients are already on treatment and the results are those taken 
during their follow-up. 
? The study also showed most of the patients (58.8%) taking medical 
treatment. Only 2.9% received radioactive therapy and none of the 
patients undergone surgery. Aibright et al declared that radioactive 
therapy is the treatment of choice in Grave’s disease. He also 
mentioned that thyroidectomy is rarely performed in patients with 
Graves’ disease in the US. 
? Internationally the radioactive therapy is becoming the corner-
stone in management of thyrotoxicosis for all ages. 
 
 
  
CONCLUSIONS 
 
? Grave’s disease is the commonest cause of hyperthyroidism in 
patients with thyrotoxicosis in the Khartoum Teaching Hospital. 
? TSI detection in the sera of patients with hyperthyroidism is crucial 
to diagnosis of Graves’ disease. 
? Dislike to hot weather and palpitation are major complaints of 
patients with Grave’s disease. 
? Proptosis is a major sign in patients with Graves’ disease. 
? Onycholysis is common in patients with Graves disease. 
? Pretibial myxaedema and thyroid acropachy, although are unique 
to Graves’ disease, both are rare clinical findings. 
 
  
RECOMMENDATIONS 
 
- High clinical suspicion is needed for diagnosis of Graves’ disease 
due to its wide variations in the clinical patterns. 
- Accurate diagnosis of Graves’ disease should be achieved by 
detection of thyroid stimulating immunoglobulins (TSI) in the 
patient serum using the radioimmunoassay assay (RIA). 
- Field studies are needed regarding thyroid diseases especially in 
Western Sudan in order to prevent late presentation and major 
complications. 
- More studies are awaited in the evaluation of radioactive iodine 
therapy in Sudan, so as to extend its use in the management of 
Graves’ disease. 
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Questionnaire 
File No:                             Serial No:  
Sex:                                 Age: 
Residence:                      Occupation: 
Marital Status:            Tribe: 
Socio—economic status: Low             Moderate             High   
Duration of Thyroid disease: 
Symptoms at presentation: 
- Wt Loss     - Goitre 
- Tremors     - Palpitation 
- Frequent stool     - Irritability  
- Sweating     - Dislike to hot weather 
- Oligomenorrhoea   - Infertility 
- Others…………………………………… 
Signs: 
- Tachycardia     - Proptosis 
- Goitre      - Bruit over the gland 
- A.F.       - Onycholysis  
- Acropachy      - Pretibial Myxaedema  
- Ophthalmoplegia     - Lidlag  
- Optic nerve compression   - Anaemia   
- Others 
 
Last Lab investigate: 
TSH  
T3 
T4  
TSI  
Has the patient received treatment  Yes     No 
o If yes specify 
o Beta blocker 
o Anti- thyroid drugs 
o Radioactive- iodine 
o Surgery 
 
 
 
 
